INTERFERON ALFA-2A
drugOn this page
Also known as AlpheonCanferonCanferon aCha-ifnalpha2aRecombinant human interferon-alfa-2aRO-228181Roferon aRoferon-aINTERFERON-ALFA2A
Summary
Interferon Alfa-2A (CHEMBL2108508) is an approved protein (ATC L03AB04); indicated across 16 conditions including neoplasm and melanoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: L03AB04
- Indications: 16 conditions
- Clinical trials: 20
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108508 |
| Name | INTERFERON ALFA-2A |
| Type | Protein |
| Max phase | 4 |
| ATC | L03AB04 |
Also known as: Alpheon, Canferon, Canferon a, Cha-ifnalpha2a, Interferon alfa-2a, INTERFERON ALFA-2A, Recombinant human interferon-alfa-2a, RO-228181, Roferon a, Roferon-a, INTERFERON-ALFA2A
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
16 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| melanoma | 3 | MONDO:0005105 | EFO:0000756 |
| renal cell carcinoma | 3 | MONDO:0005086 | EFO:0000681 |
| acute lymphoblastic leukemia | 3 | MONDO:0004967 | EFO:0000220 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| metastatic melanoma | 3 | MONDO:0005191 | EFO:0002617 |
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
| kidney cancer | 3 | MONDO:0002367 | MONDO:0002367 |
| Behcet disease | 3 | MONDO:0007191 | EFO:0003780 |
| retinal vasculitis | 3 | MONDO:0006950 | EFO:1001156 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| plasma cell myeloma | 2 | MONDO:0009693 | EFO:0001378 |
| chronic hepatitis C virus infection | 2 | MONDO:0005354 | EFO:0004220 |
| hairy cell leukemia | 2 | MONDO:0018935 | EFO:1000956 |
| psoriasis | 1 | MONDO:0005083 | EFO:0000676 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 20.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE1 | 5 |
| PHASE3 | 3 |
| PHASE4 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00172809 | PHASE4 | COMPLETED | Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease |
| NCT00381953 | PHASE3 | COMPLETED | High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV |
| NCT00502034 | PHASE3 | COMPLETED | Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. |
| NCT03209219 | PHASE3 | COMPLETED | Interferon α2a Versus Cyclosporine for Refractory Behçet’s Disease Uveitis |
| NCT00000687 | PHASE2 | COMPLETED | Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi’s Sarcoma |
| NCT00000754 | PHASE2 | COMPLETED | A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3 |
| NCT00001567 | PHASE2 | COMPLETED | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia |
| NCT00008463 | PHASE2 | COMPLETED | A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) |
| NCT00433069 | PHASE2 | COMPLETED | Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone |
| NCT00520403 | PHASE2 | COMPLETED | A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. |
| NCT00719264 | PHASE2 | COMPLETED | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer |
| NCT00796757 | PHASE2 | COMPLETED | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). |
| NCT02159482 | PHASE2 | TERMINATED | Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines |
| NCT02340962 | PHASE2 | COMPLETED | Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection |
| NCT00000696 | PHASE1 | COMPLETED | A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease |
| NCT00000725 | PHASE1 | COMPLETED | A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi’s Sarcoma |
| NCT00000764 | PHASE1 | COMPLETED | Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection. |
| NCT00000967 | PHASE1 | COMPLETED | The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children |
| NCT00001113 | PHASE1 | COMPLETED | A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi’s Sarcoma |
| NCT03771677 | Not specified | UNKNOWN | To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).